Reaction

Deafness Unilateral reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,430 reports · 128 co-occurring drugs

As of the last recalculation, Deafness Unilateral appears in 5,430 FAERS reports alongside 128 co-occurring drug terms. The strongest observed disproportionality signal is AGALSIDASE BETA (PRR 6.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Agalsidase Beta	16	6.7	6.7
Tadalafil	162	6.4	6.4
Trimethoprim	17	5.5	5.5
Timolol Maleate	14	5.4	5.4
Meclizine Hcl 12.5Mg	19	5.4	5.4
Meclizine Hcl 25Mg	19	5.4	5.4
Meclizine Hcl 12.5 Mg	19	5.4	5.4
Meclizine Hcl 25 Mg	19	5.4	5.4
Meclizine Hydrochloride	27	5.3	5.3
Meclizine	21	4.9	5.0
Amikacin	21	4.7	4.7
Sildenafil Citrate	150	4.6	4.6
Zidovudine	14	4.0	4.0
Captopril	10	4.0	4.0
Minocycline	12	4.0	4.0
Gentamicin Sulfate	16	3.9	3.9
Azithromycin Dihydrate	59	3.9	3.9
Valsartan And Hydrochlorothiazide	13	3.7	3.7
Azithromycin Monohydrate	39	3.6	3.6
Mometasone	17	3.6	3.6
Moxifloxacin	13	3.5	3.5
Azithromycin	37	3.5	3.5
Acalabrutinib	11	3.5	3.5
Nicotine Polacrilex Mini	13	3.3	3.3
Nicotine Polarilex	13	3.3	3.3
Gentamicin	11	3.2	3.2
Diroximel Fumarate	10	3.2	3.2
Cladribine	8	3.2	3.2
Riociguat	27	3.2	3.2
Risankizumab-Rzaa	64	3.0	3.0
Rizatriptan Benzoate	8	3.0	3.0
Interferon Beta-1B	15	3.0	3.0
Ciprofloxacin Hydrochloride And Hydrocortisone	16	3.0	3.0
Deferasirox	20	2.9	2.9
Ibrutinib	59	2.8	2.8
Zoledronic Acid	29	2.8	2.8
Ezetimibe And Simvastatin	11	2.8	2.8
Upadacitinib	58	2.7	2.7
Dimethyl Fumarate	86	2.7	2.7
Alendronate Sodium Tablet	13	2.7	2.7
Clarithromycin	24	2.7	2.7
Finasteride	42	2.7	2.7
Liothyronine Sodium	6	2.6	2.6
Peginterferon Beta-1A	9	2.6	2.6
Insulin Human	27	2.6	2.6
Interferon Beta-1A	128	2.6	2.6
Ranolazine	7	2.6	2.6
Goserelin	9	2.6	2.6
Peginterferon Alfa-2A	35	2.5	2.5
Nilotinib	19	2.5	2.5
Botulinum Toxin Type A	8	2.5	2.5
Macitentan	44	2.4	2.4
Amlodipine Besylate And Valsartan	7	2.4	2.4
Raloxifene Hydrochloride	9	2.4	2.4
Sildenafil	35	2.3	2.3
Selexipag	15	2.2	2.2
Adalimumab	393	2.2	2.2
Valacyclovir	24	2.2	2.2
Brinzolamide	5	2.2	2.2
Azelastine	10	2.1	2.1
Benralizumab	11	2.1	2.1
Latanoprost	27	2.1	2.1
Ravulizumab	7	2.0	2.0
Erlotinib	5	2.0	2.0
Imatinib Mesylate	14	1.9	1.9
Ribavirin	32	1.9	1.9
Apixaban	33	1.9	1.9
Erlotinib Hydrochloride	6	1.8	1.8
Fingolimod Hcl	41	1.8	1.8
Ado-Trastuzumab Emtansine	4	1.8	1.8
Norepinephrine	5	1.8	1.8
Tenofovir Disoproxil Fumarate Tablets	4	1.8	1.8
Travoprost	4	1.8	1.8
Canakinumab	5	1.8	1.8
Lisdexamfetamine Dimesylate	15	1.7	1.7
Onabotulinumtoxina	35	1.7	1.7
Natalizumab	82	1.7	1.7
Vismodegib	4	1.7	1.7
Siponimod	4	1.7	1.7
Dapagliflozin	14	1.7	1.7
Ambrisentan	55	1.7	1.7
Lurasidone Hydrochloride	9	1.6	1.7
Armodafinil	9	1.6	1.6
Venetoclax	26	1.6	1.6
Insulin Glargine	102	1.6	1.6
Cetuximab	13	1.6	1.6
Insulin Lispro	57	1.6	1.6
Elexacaftor, Tezacaftor, And Ivacaftor	5	1.5	1.5
Abemaciclib	8	1.5	1.5
Treprostinil	50	1.5	1.5
Asfotase Alfa	4	1.5	1.5
Derma Foam Excel Hand Sanitizer	3	1.4	1.4
Ethanol	3	1.4	1.4
Ocrelizumab	23	1.4	1.4
Glecaprevir And Pibrentasvir	4	1.4	1.4
Ofatumumab	12	1.4	1.4
Isotretinoin	17	1.3	1.3
Denosumab	69	1.3	1.3
Oral Semaglutide	25	1.3	1.3
Crizotinib	4	1.2	1.2
Nirmatrelvir And Ritonavir	17	1.2	1.2
Crisaborole	3	1.2	1.2
Teriflunomide	14	1.2	1.2
Lifitegrast	5	1.2	1.2
Encorafenib	3	1.2	1.2
Glatiramer Acetate	18	1.2	1.2
Medroxyprogesterone Acetate	15	1.2	1.2
Dalfampridine	21	1.1	1.1
Aflibercept	9	1.1	1.1
Galcanezumab-Gnlm	9	1.1	1.1
Minoxidil Foam 5% (Womens)	9	1.0	1.0
Enzalutamide	16	1.0	1.0
Ranibizumab	7	1.0	1.0
Apalutamide	3	1.0	1.0
Tafamidis	3	1.0	1.0
Sacubitril And Valsartan	29	1.0	1.0
Drospirenone And Ethinyl Estradiol	10	0.9	0.9
Pirfenidone	9	0.8	0.8
Osimertinib	7	0.8	0.8
Ledipasvir And Sofosbuvir	4	0.8	0.8
Minoxidil	9	0.8	0.8
Orlistat	5	0.7	0.7
Somatropin	13	0.7	0.7
Erenumab-Aooe	9	0.6	0.6
Evolocumab	26	0.6	0.6
Tirzepatide	25	0.6	0.6
Apremilast	20	0.5	0.5
Pimavanserin Tartrate	5	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.